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Background: Interstitial lung diseases (ILD) comprise a heterogeneous group of disorders, and
when diagnosed at the stage of pulmonary fibrosis, the underlying lung disease can sometimes
be difficult to identify. The aim of the present study was to determine whether there are dif-
ferences in FENO (fraction of exhaled nitric oxide) between different subtypes of fibrotic ILD.
Methods: Sixty-one patients, with honeycombing on computed tomography (CT) scan, and
whose FENO levels had been measured during chronic dyspnoea evaluation, were divided into
four groups based on pulmonary fibrosis aetiology: idiopathic pulmonary fibrosis (IPF), chronic
hypersensitivity pneumonitis (HP), connective tissue disease-associated ILD disorders (CTD-
ILD), drug-induced pneumonia. The FENO values of each group were compared and CT scan fea-
tures were analysed to identify the mechanisms involved in FENO change.
Results: The median FENO value of patients with chronic HP was 51 ppb (IQR 36e74), higher
than that of the other groups (22 ppb (IQR 17e30) in IPF, 19 ppb (IQR 17e21) in drug-
induced pneumonia, and 25 ppb (IQR 17e37) for CTD-ILD; p Z 0.008). At the cut-off value
of 41 ppb, the optimal sensitivity and specificity to diagnose HP with FENO were respectivelyntration of exhaled NO; DIP, drug induced pneumonia; FENO, fractional exhaled nitric oxide; FEF
w; FEV1, Forced Expiratory Volume in 1 s; GGO, ground-glass opacities; HP, hypersensitivity pneu-
interstitial lung disease; CTD-ILD, connective tissue disease-associated ILD disorders; IPF, idiopathic
g airway flux; SSC, systemic sclerosis; TLC, Total Lung Capacity; VC, vital capacity.
neumologie, CHRU Tours, 2 Boulevard Tonnelle, 37032 Tours, France. Tel.: þ33 2 47 47 82 29; fax:þ33
laurent.guilleminault@univ-tours.fr (L. Guilleminault).
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1790 L. Guilleminault et al.76.9% and 85.4%. On CT scans, only extensive lobular areas with decreased attenuation, a
recognized marker of bronchiolar disease, were associated with high FENO values (pZ 0.0002).
Conclusion: FENO could be a tool for differentiating chronic HP from other types of pulmonary
fibrosis. The mechanism involved seems to be bronchiolar disease.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Interstitial lung diseases (ILD) comprise a group of het-
erogeneous disorders which can lead to pulmonary
fibrosis with a poor prognosis [1,2]. ILD can be idiopathic,
or the consequence of an underlying disease which is
sometimes difficult to identify when the diagnosis is
made at the stage of fibrosis, characterized by honey-
combing on computed tomography (CT) scan. However, it
is important to identify the underlying lung disease, as it
may influence survival or treatment. For example, the
survival rate for systemic sclerosis with ILD is better than
for other connective tissue diseases with ILD, and the
prognosis for non-specific interstitial pneumonia (NSIP) is
much better than for idiopathic fibrosis (IPF) [3,4]. In
terms of treatment, oral corticosteroid may be used in
hypersensitivity pneumonitis (HP), a cause of ILD, but it
has little or no effect on IPF [1,5,6]. Furthermore, the
diagnosis of HP in the context of ILD is crucial, so that
any contact with the antigen responsible for the disease
can be avoided [6].
Patient care could therefore be improved by identifying
a marker to differentiate causes of honeycombing. In HP,
IgG precipitin to the antigen may be missed in the early
stages of the disease. Thoracic CT may help to differentiate
between causes of honeycombing [7]. Lobular areas of
decreased attenuation or centrilobular nodules are mostly
observed in HP. Conversely, basal predominance of honey-
combing is mostly seen in IPF [7]. However, CT scan fea-
tures are not specific and surgical lung biopsy is sometimes
required to establish the diagnosis [7,8].
Nitric oxide (NO) is produced by airway epithelial cells
in the respiratory tract, and by airway and circulatory
endothelial cells in both large and peripheral airways.
Fractional exhaled nitric oxide (FENO) is commonly used as
a marker of airway inflammation in asthma to determine
the optimal dose of inhaled corticosteroid [9,10]. There
have been few studies of FENO in ILD, and they have mostly
concerned systemic sclerosis and had conflicting results
[11,12]. Furthermore, to the best of our knowledge, no
study has focused on FENO as a marker of pulmonary
fibrosis aetiology.
The aim of the present study was to determine whether
there are differences in FENO between different subtypes of
fibrotic ILD. We carried out a retrospective analysis of FENO
data of patients presenting with dyspnoea and honey-
combing on CT. Patients were divided into four groups:
chronic HP, IPF, connective tissue disease-associated ILD
disorders (CTD-ILD), and drug-induced pneumonia. FENO
values were compared between groups, and CT scan fea-
tures were analysed to investigate the relationship be-
tween anatomic lesion and increase in FENO.Sample and methods
Study sample
The files of patients with pulmonary fibrosis attending the
respiratory medicine department of Tours University Hos-
pital between June 2009 and June 2012 were reviewed.
Inclusion criteria were honeycombing on CT scan and
measurement of fractional exhaled nitric oxide (FENO) as
part of chronic dyspnoea management (n Z 74). Time to
onset of dyspnoea must be superior to 3 months. Patients
with a recent increase of dyspnoea were excluded. Hon-
eycombing was defined as subpleural clustered cystic air-
spaces with thick fibrous walls, as described in the glossary
of the Fleischner Society [13]. Patients were excluded if
they had symptoms of asthma as defined by GINA, or post-
bronchodilatator improvement of FEV1 on pulmonary
function tests [14]. Patients were also excluded if they had
no clear aetiology of pulmonary fibrosis and if surgical bi-
opsy was not available (n Z 13).
Causes of pulmonary fibrosis were divided into four
groups: chronic hypersensitivity pneumonitis (HP), idiopathic
pulmonary fibrosis (IPF), connective tissue disease with lung
involvement (CTD-ILD), and drug-induced pneumonia (DIP).
Diagnosis of IPF was based on ATS/ERS criteria [1]. Diagnosis
of chronic HP was based on the criteria established by
Lacasse et al. or histological features [15e17]. CTD-ILD was
identified on the basis of criteria described in the literature
[18e20]. The pharmacological criteria proposed by Edwards
et al. were used to diagnose drug-induced pneumonia [21].
Precipitins were negative for all patients in the IPF, CTD-ILD
and DIP groups and none of them had allergen exposure.
Diagnosis was made by two lung specialists who established a
consensus. They were blinded to FENO values and CT quan-
tification of lesions performed by radiologists. Connective
tissue diseases were confirmed by a rheumatologist or an
internal medicine physician.
Data concerning age, sex, smoking habits, pulmonary
function tests, lactate dehydrogenase serum level (LDH),
blood eosinophilia, oxygen treatment and immunosuppressive
treatment (including corticosteroid treatment)werecollected
to rule out potential confounding factors of FENO values. The
study was approved by the Institutional Review Board of
the French society for respiratory medicine e Socie´te´ de
Pneumologie de Langue Franc¸aise e (CEPRO# 2011-028). All
patients gave their informed consent for inclusion in this study.Pulmonary function tests
Lung function tests were performed using Sensormedics
Vmax Encore plethysmography (Carefusion; San Diego,
Exhaled NO and pulmonary fibrosis 1791CA). Forced Vital Capacity (FVC), Total Lung Capacity
(TLC), Forced Expiratory Volume in one second (FEV1), and
25e75% Forced Expiratory Flow (FEF 25e75) values were
expressed as percentages of predicted values according to
gender, weight and age. Measurements were performed
following ATS/ERS recommendations [22]. The predicted
values were those of the ERS [23]. FENO values were ob-
tained using an electrochemical device (Hypair FeNO,
Medisoft; Sorinnes, Belgium) following ATS/ERS recom-
mendations [24]. Repeated and reproducible exhalations
were performed until at least two NO plateau values
differing by less than 10% were obtained. Flow rate exha-
lation was 50 ml/s. The FENO value retained was the mean
of two reproducible measurements. In patients using oxy-
gen, measurements were performed 30 min after stopping
oxygen. FENO was expressed in parts per billion (ppb). FENO
values were obtained 12 h at least after tobacco
consumption.
Thoracic computed tomography (CT)
Thoracic CT scans were performed on all patients using a
64-slice Philips CT Scanner (Philips DA Best, Netherlands).
CT scans were evaluated by two thoracic radiologists blin-
ded to the patients’ clinical and functional details, in
accordance with previously published criteria [7]. The two
observers easily established a consensus about the quanti-
fication of lesions. In brief, areas of ground-glass opacities
(GGO) were classified as involving less than 25%, 25e50%, or
more than 50% of the lung parenchyma. The extent of
lobular areas with decreased attenuation was evaluated by
counting the number of secondary lobules with decreased
attenuation on all inspiratory images, and classified in two
categories: class 1 (up to four lobules and involving less
than four lobes), and class 2 (five or more lobules in more
than four lobes, the lingula being considered as a separate
lobe). Lobular areas with decreased attenuation were focal
zones with parenchymal decreased attenuation associated
with decreased vascularity [13]. Areas of consolidation or
centrilobular nodules were also identified.
Statistical analysis
Continuous data were described with medians and inter-
quartile ranges (IQR). Categorical data were expressed as
percentages. Continuous data for each pulmonary fibrosis
group were compared using the KruskalleWallis test. Fisher
exact tests were used to compare category data for each
pulmonary fibrosis group. The ManneWhitney test was used
to compare FENO values with CT scan parameters. Statisti-
cal significance was defined as a p-value <0.05. Receiver
operator characteristics (ROC) curves and area under curve
(AUC) were used to assess FENO as a potential marker of
chronic HP. Sensitivity and specificity of FENO for chronic HP
diagnosis were also defined.
Results
Pulmonary fibrosis causes
Data from 61 patients with pulmonary fibrosis were ana-
lysed. Causes of pulmonary fibrosis were divided into fourgroups. Eighteen patients (29.%) had IPF, 17 with UIP
pattern on CT scan and 1 with an inconsistent pattern on CT
scan but with a histological UIP pattern on surgical lung
biopsy. Thirteen patients (21%) had chronic HP, including six
with farmer’s lung, and four with bird-breeder’s lung. For
the other three patients in this group, there was no clear
evidence of exposure, and diagnosis was based on histo-
logical features. CTD-ILD was identified in 22 patients (36%)
including four with rheumatoid arthritis, three with Sjo¨gren
syndrome, three with dermatomyositis, two with systemic
sclerosis and one with mixed connective tissue disease. This
group included nine patients with signs of undifferentiated
connective tissue disease. Among the eight patients (13%)
with drug-induced pneumonia, amiodarone was suggested
to be involved in pulmonary fibrosis in four cases, and ergot
alkaloid, simvastatin, bleomycin and indapamide in one
case each.
Clinical and functional characteristics
The characteristics of patients with pulmonary fibrosis are
summarized in Table 1. Clinical, biological, and functional
parameters were similar in all groups. There was no sta-
tistical difference for age, sex ratio, blood eosinophilia, or
LDH (Table 1). Patients with drug-induced pneumonia had a
median age of 80 years (IQR 71e84) which was older than
the other patients but the difference was not statistically
significant The percentage of smokers was lower in patients
with chronic HP than in the other groups, but the difference
was not statistically significant (p Z 0.79). In smokers,
cigarette consumption was lower in chronic HP but the
difference was also not significant (p Z 0.14). Time of
smoking cessation was significantly longer in chronic HP
patients than in others (p Z 0.03). Median FVC and TLC
values were lower in patients with chronic HP (68% (IQR
54e90) and 62% (IQR 53e83) of predicted values respec-
tively) than other groups, but the difference was not sta-
tistically significant (p Z 0.26 and p Z 0.21 respectively).
Immunosuppressive treatments are detailed in Table 1. In
the chronic HP group, one patient received rapamycin for
chronic kidney disease. The number of patients receiving
immunosuppressive treatment was lower in the IPF group
(22%), but the difference was not statistically significant
(p Z 0.11). The number of patients treated with steroids
and the steroid dosage were similar between groups
(p Z 0.28 and p Z 0.74, respectively). BAL cell count was
higher in chronic HP patients, but there was only a ten-
dency (p Z 0.09).
FENO values in pulmonary fibrosis
FENO values were higher in patients with chronic HP than in
those with other causes (p Z 0.008) (Fig. 1). Patients with
chronic HP had a median FENO value of 51 ppb (IQR 36e74)
compared with 22 ppb (IQR 17e30) in IPF, 19 ppb (IQR
17e21) in drug-induced pneumonia, and 25 ppb (IQR 17e37)
for CTD-ILD. ROC curve analysis showed that FENO
values are a good marker for predicting hypersensitivity
pneumonitis (Fig. 2). At the cut-off value of 41 ppb, the
optimal sensitivity and specificity were respectively 76.9%
and 85.4%.
Table 1 Comparison of clinical, biological and functional parameters for each cause of honeycombing. Data are presented in
median (interquartile range) or n (%). Lung function test values are expressed as percentages of predicted values. DLCO and KCO
are expressed in mL/min/mmHg. FVC: Forced Vital Capacity; TLC: Total Lung Capacity; FEV1: Forced Expiratory Volume in 1 s;
DLCO: diffusing capacity of the lung for carbon monoxide; TLCO: transfer factor of the lung for carbon monoxide; CTD-ILD:
Connective tissue disease-associated ILD disorders. Steroid dosage is expressed in prednisone equivalent.
Chronic HP
(n Z 13)
IPF
(n Z 18)
Drug-induced
pneumonia
(n Z 8)
CTD-ILD
(n Z 22)
p
Age 69 (66e78) 66 (62e78) 80 (71e84) 71 (61e81) 0.10
Sex ratio (F/M) 2/11 2/16 2/6 9/13 0.14
Smokers: 6 (46.1) 11 (61.1) 5 (62.5) 11 (50) 0.79
Active 0 (0) 2 (11) 1 (12.5) 0 (0)
Pack/year 15 (8e30) 33 (28e53) 30 (25e48) 25 (20e75) 0.14
Time of smoking cessation (years) 30.5 (27.3e35.8) 17 (1e21.8) 20 (6e24.5) 20 (11e30) 0.03
Blood
Eosinophilia (G/l)
275 (68e303) 170 (90e330) 248 (148e345) 215 (80e500) 0.91
LDH (UI/l) 508 (360e673) 481 (424e555) 412 (357e604) 443 (393e568) 0.85
FVC% pred 68 (54e90) 82 (64e98) 95 (84e108) 87 (65e97) 0.26
TLC% pred 62 (53e84) 73 (58e92) 83 (77e90) 68 (84e60) 0.21
FEV1% pred 71 (58e90) 79 (69e99) 96 (82e103) 80 (63e94) 0.22
FEV1/FVC% 80 (78e83) 80 (72e86) 74 (70e81) 79 (70e89) 0.67
DLCO 51 (38e58) 45 (28e53) 50 (43e72) 44 (30e59) 0.69
TLCO 90 (83e115) 83 (60e105) 83 (62e120) 80 (55e94) 0.24
pO2 (mmHg) 76 (63e82) 72 (64e86) 67 (61e76) 77 (65e84) 0.51
PCO2 (mmHg) 40 (35e43) 39 (35e43) 38 (34e43) 39 (32e42) 0.85
Oxygen 3 (23) 4 (22) 2 (25) 5 (23) 0.99
Immunosuppressive treatment: 7 (54) 4 (22) 4 (50) 13 (59) 0.11
Steroids 5 (38.5) 3 (17) 4 (50) 9 (41) 0.28
Steroid dosage (mg/j) 18 (11e20) 12.5 (8e19) 12.5 (10e34) 10 (6e30) 0.74
Azathioprine 1 (7.75) 0 (0) 0 (0) 0 (0)
Rapamycin 1 (7.75) 0 (0) 0 (0) 0 (0)
Leflunomide 0 (0) 0 (0) 0 (0) 1 (4.5)
Infliximab 0 (0) 0 (0) 0 (0) 1 (4.5)
Thalidomide 0 (0) 0 (0) 0 (0) 1 (4.5)
Mycophenolate mofetil 0 (0) 1 (5) 0 (0) 1 (4.5)
BAL cell count (cells/mm3) 268 (142e783) 160 (118e261) 223 (114e318) 116 (98e150) 0.09
FENO (ppb) 51 (36e74) 22 (17e30) 19 (17e21) 25 (17e37) 0.008
1792 L. Guilleminault et al.There was no correlation between PFT findings and FENO
in chronic HP patients (data not shown). FENO values were
similar in patients with or without immunosuppressive
treatment (27 ppb (IQR 17e39) versus 23 ppb (IQR
17.5e43.5) respectively, p Z 0.97), and also in patients
with or without steroids (28 ppb (IQR 17e43) versus 25 ppb
(IQR 18.5e43.5) respectively p Z 0.93). Steroid dosages
were not correlated with FENO values.
FENO values and CT scan parameters
CT scan parameters of bronchiolar or alveolar features
were evaluated to investigate the increase in FENO values
in chronic HP (Supplementary Data). Values were signifi-
cantly higher in patients with extensive lobular areas with
decreased attenuation (class 2) than in those in class 1
(Fig. 3A). The median FENO value in patients in class 2 was
47 ppb (IQR 37e62), compared to 22 ppb (IQR 17e32) in
patients in class 1 (p Z 0.0002). The extent of ground-
glass opacities was not statistically correlated with FENO
values, as shown in Fig. 3B. Median FENO values were25 ppb (IQR 17e44), 34 ppb (IQR 19e47), and 19 ppb
(16e24) in patients with less than 25%, 25e50%, and more
than 50% of GGO respectively (pZ 0.19). FENO values were
not correlated with bronchiolar nodules or consolidation
(pZ 0.24 and pZ 0.73, respectively) (Fig. 3C, D). Median
FENO values were 30 ppb (IQR 19e49) and 23 ppb (IQR
17e34) in patients with and without centrilobular nodules
respectively, and 26 ppb (IQR 13e56) and 25 ppb (IQR
19e43) in patients with and without consolidation
respectively. Other features were analysed on CT scan,
such as fibrosis localization, fibrosis severity, subpleural
sparing, but none of them were correlated with FENO
values (data not shown).
Discussion
In our study, patients with chronic HP had significantly
higher FENO values than those in the groups of other aeti-
ologies of pulmonary fibrosis (pZ 0.008). This suggests that
FENO could help identify chronic HP as the origin of pul-
monary fibrosis in patients with honeycombing on CT scan.
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Figure 1 Median FENO value for aetiologies of pulmonary
fibrosis. IPF: Idiopathic pulmonary fibrosis. (*: pZ 0.008). IPF:
idiopathic pulmonary fibrosis, chronic HP: chronic hypersensi-
tivity pneumonitis; CTD-ILD: connective tissue disease-
associated ILD disorders.
Exhaled NO and pulmonary fibrosis 1793FENO values were higher in patients with extensive lobular
areas with decreased attenuation, indicating that FENO may
be a marker of bronchiolar damage in HP.
Clinical and functional parameters were similar between
all groups of pulmonary fibrosis except for smoking status.
We found that the percentage of smokers was lower in
patients with chronic HP than in the other groups, but the
difference was not statistically significant. Moreover, time
of smoking cessation was significantly longer in chronic HPFigure 2 Receiver operating characteristics (ROC) curve
analysis of FENO values for diagnosis of hypersensitivity pneu-
monitis. At the cut-off value of 41 ppb, sensitivity and speci-
ficity are respectively 76.9% and 85.4%.patients than in others (p Z 0.03). It has been well docu-
mented that active smoking decreases FENO [25e27].
However, there were only two active smokers in our cohort
and excluding these two patients from the statistical
analysis did not alter our results. Several studies have
assessed FENO values in ex-smokers with conflicting results.
One study showed that FENO decreases in ex-smokers
compared to healthy subjects (17.7 versus 22.8 ppb,
respectively) [25]. Two studies showed opposite results. In
these studies, ex-smokers and healthy subjects had similar
FENO values (17.1 versus 16.9 ppb respectively in one
study, and 18.4 versus 17.5 ppb respectively in the other)
[26,27]. If ex-smoking status modifies FENO, the proportion
of decrease is very low compared to the difference
observed between pulmonary fibrosis groups in our study.
Smoking status does not explain the considerable increase
in FENO in chronic HP patients in our study.
Exhaled nitric oxide has only been evaluated in patients
with HP in one previous study [28]. The authors evaluated
alveolar concentration of NO and bronchial NO flux but not
FENO. They analysed exhaled alveolar and bronchiolar NO
in 40 patients with asthma, 17 with “alveolitis”, and 57
healthy control subjects. Patients with “alveolitis”
included seven farmers with HP and 10 patients with IPF
who were compared with asthmatic patients and controls.
Bronchial NO flux was higher in asthma patients than in the
“alveolitis” group (including HP and IPF) and healthy con-
trols. Alveolar NO concentration was higher in “alveolitis”
patients than in the asthma and control groups. In that
study, HP and IPF were assessed together and no conclusion
can be drawn regarding exhaled NO and HP or IPF inde-
pendently. However, the two diseases have different
mechanisms and treatment. For this reason, we analysed
FENO dividing causes of honeycombing into four groups of
pulmonary fibrosis: chronic HP, IPF, drug-induced pneu-
monia, and CTD-ILD. In our study, we chose to assess FENO
and not alveolar concentration of NO or bronchial NO flux,
because only FENO is available in most lung function test
labs.
In ILD, exhaled nitric oxide has mainly been assessed in
systemic sclerosis (SSC) with lung involvement. However,
evaluation was usually based on alveolar concentration of
exhaled NO (CANO) and conducting airway flux (J’awNO)
rather than on FENO. Only one study evaluated FENO in SSC,
and no increase in concentration was found [29]. With re-
gard to CANO and J’awNO, findings are conflicting, possibly
because there is no standardized method of measuring
exhaled NO and no precise definition of ILD features on CT
scan; one study reported no difference between SSC with
and without ILD [26], four studies reported higher CANO
values in SSC with than without ILD [11,30e32], and two
studies reported lower CANO values in SSC without than
those with ILD [12,33]. In another study, exhaled NO levels
were found to be higher in IPF than in SSC patients, which
were in turn higher than in controls [34]. In that study,
levels were evaluated from the exhaled NO peak. Exhaled
NO has also been assessed in asbestosis; FENO values were
higher in asbestosis patients than in healthy subjects [35].
CT scan is considered as a useful tool to classify ILD in
terms of histopathological alteration and even aetiology.
However, at the stage of fibrosis characterized by honey-
combing, it is more difficult to identify specific features.
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HP in patients with pulmonary fibrosis. At the cut-off of
41 ppb, FENO can be used to diagnose chronic HP with a
sensitivity and specificity of 76.9% and 85.4%, respectively.
In a study conducted by Silva et al., the sensitivity and
specificity of CT scan features enabling the diagnosis of
chronic HP were 78% and 88%, respectively, which is similar
to data obtained with FENO in our study [7]. However, the
data of the CT scan study were obtained with experienced
radiologists. FENO can be used with a calibrating device as a
marker by all physicians.
The mechanism of FENO increase in HP patients is un-
known. The main hypothesis, based on what happens in
asthma, is bronchiolar disease [9]. Histologically, HP is
characterized by a triad comprising chronic interstitial
pneumonia with peribronchiolar accentuation, bronchioli-
tis, and non-caseating granulomas [16,17]. The inflamma-
tory process involved in HP could be responsible for the
increase in the inducible nitric oxide synthase produced by
alveolar macrophages [9]. This enzyme produces nitric
oxide which has direct toxic effects on cells and can be
found in the patient’s exhaled breath. To understand the
mechanisms involved in FENO increase, we examined our
patients’ CT scans. We evaluated lobular areas of
decreased attenuation, which is reported to be significantly
more frequent in HP patients than in patients with IPF and
NSIP [7]. Patients with lobular areas of decreased attenu-
ation in class 2 (five or more lobules in more than four
lobes) had statistically higher FENO values than patients in
class 1 (p Z 0.0002). The lobular areas of decreased
attenuation are presumed to be secondary to small airway
obstruction due to cellular bronchiolitis [7]. This data is
therefore consistent with the hypothesis that FENO increaseresults from bronchiolar disease. The number of patients
with expiratory CT scan was too small to assess air trapping,
which may be a marker of bronchiolar disease. Bronchiolar
disease is also observed in connective tissue lung disease,
and some patients in this group did indeed have increased
FENO concentrations. However, the difference between the
FENO values in connective tissue disease and HP was sta-
tistically significant.
In conclusion, FENO concentration is higher in chronic HP
than in other causes of pulmonary fibrosis, which could help
diagnose chronic HP in ILD with honeycombing on CT scan.
The mechanisms involved in FENO increase is unknown, but
may involve bronchiolar disease, as suggested by extensive
lobular areas of decreased attenuation in patients with high
FENO values. Further studies are needed to confirm these
results and understand the mechanism of increased FENO in
chronic HP. Other markers should be assessed, such as
sputum eosinophilia or air trapping on CT scan. Steroid
treatment should also be assessed to determine whether
FENO could be a predictive marker of steroid sensitivity, as
demonstrated in asthma.Author contribution
L. Guilleminault MD: data collection, writing the manuscript.
A. Saint-Hilaire MD: CT scan interpretation.
O. Favelle MD: CT scan interpretation.
A. Caille MD: Statistical analysis.
E. Boissinot MD: lung function test interpretation.
AC Henriet MD: data collection.
P. Diot MD, PhD: proofreading.
S. Marchand-Adam MD, PhD: proofreading.
Exhaled NO and pulmonary fibrosis 1795Conflict of interest
No conflict of interest exists for the author or co-authors.Acknowledgements
We thank Sylvie Angelliaume, Agne`s Bauge, Sandrine Berge´,
Daniel Grimbert and Nathalie Rouillard who performed
pulmonary function tests and FENO measurements.Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.rmed.2013.07.007.References
[1] Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK,
Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH,
Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C,
Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King Jr TE,
Kondoh Y, Myers J, Mu¨ller NL, Nicholson AG, Richeldi L,
Selman M, Dudden RF, Griss BS, Protzko SL, Schu¨nemann HJ.,
ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary
Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic
pulmonary fibrosis: evidence-based guidelines for diagnosis
and management. Am J Respir Crit Care Med 2011;183(6):
788e824.
[2] Ferna´ndez Pe´rez ER, Daniels CE, Schroeder DR, St Sauver J,
Hartman TE, Bartholmai BJ, Yi ES, Ryu JH. Incidence, preva-
lence, and clinical course of idiopathic pulmonary fibrosis: a
population-based study. Chest 2010;137(1):129e37.
[3] Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB,
Colby TV, Travis WD, Mumford JA, Murray S, Flint A,
Lynch 3rd JP, Martinez FJ. Radiological versus histological
diagnosis in UIP and NSIP: survival implications. Thorax 2003;
58(2):143e8.
[4] Su R, Bennett M, Jacobs S, Hunter T, Bailey C, Krishnan E,
Rosen G, Chung L. An analysis of connective tissue disease-
associated interstitial lung disease at a US Tertiary Care
Center: better survival in patients with systemic sclerosis. J
Rheumatol 2011;38(4):693e701.
[5] Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for
idiopathic pulmonary fibrosis. Cochrane Database Syst Rev
2003;(3). CD002880.
[6] Girard M, Lacasse Y, Cormier Y. Hypersensitivity pneumonitis.
Allergy 2009;64(3):322e34.
[7] Silva CI, Mu¨ller NL, Lynch DA, Curran-Everett D, Brown KK,
Lee KS, Chung MP, Churg A. Chronic hypersensitivity pneu-
monitis: differentiation from idiopathic pulmonary fibrosis
and nonspecific interstitial pneumonia by using thin-section
CT. Radiology 2008;246(1):288e97.
[8] Sung A, Swigris J, Saleh A, Raoof S. High-resolution chest to-
mography in idiopathic pulmonary fibrosis and nonspecific
interstitial pneumonia: utility and challenges. Curr Opin Pulm
Med 2007;13(5):451e7.
[9] Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC,
Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR,
Zamel N. Exhaled nitric oxide in pulmonary diseases: a
comprehensive review. Chest 2010;138(3):682e92.
[10] Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use
of exhaled nitric oxide measurements to guide treatment in
chronic asthma. N Engl J Med 2005;352:2163e73.[11] Tiev KP, Cabane J, Aubourg F, Kettaneh A, Ziani M, Mouthon L,
Duong-Quy S, Fajac I, Guillevin L, Dinh-Xuan AT. Severity of
scleroderma lung disease is related to alveolar concentration
of nitric oxide. Eur Respir J 2007;30(1):26e30.
[12] Malerba M, Radaeli A, Ragnoli B, Airo’ P, Corradi M,
Ponticiello A, Zambruni A, Grassi V. Exhaled nitric oxide levels
in systemic sclerosis with and without pulmonary involve-
ment. Chest 2007;132(2):575e80.
[13] Hansell DM, Bankier AA, MacMahon H, McLoud TC, Mu¨ller NL,
Remy J. Fleischner Society: glossary of terms for thoracic
imaging. Radiology 2008;246(3):697e722.
[14] Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM,
FitzGerald M, Gibson P, Ohta K, O’Byrne P, Pedersen SE,
Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy
for asthma management and prevention: GINA executive
summary. Eur Respir J 2008;31(1):143e78.
[15] Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M,
Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV,
Schuyler M, Cormier Y., HP Study Group. Clinical diagnosis of
hypersensitivity pneumonitis. Am J Respir Crit Care Med 2003;
168(8):952e8.
[16] Lima MS, Coletta EN, Ferreira RG, Jasinowodolinski D,
Arakaki JS, Rodrigues SC, Rocha NA, Pereira CA. Subacute and
chronic hypersensitivity pneumonitis: histopathological pat-
terns and survival. Respir Med 2009;103(4):508e15.
[17] Coleman A, Colby TV. Histologic diagnosis of extrinsic allergic
alveolitis. Am J Surg Pathol 1988;12:514e8.
[18] Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.
The American Rheumatism Association 1987 revised criteria
for the classification of rheumatoid arthritis. Arthritis Rheum
1988;31(3):315e24.
[19] Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM,
Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI,
Kassan SS, Pillemer SR, Talal N, Weisman MH., European Study
Group on Classification Criteria for Sjo¨gren’s Syndrome.
Classification criteria for Sjo¨gren’s syndrome: a revised
version of the European criteria proposed by the American-
European Consensus Group. Ann Rheum Dis 2002;61(6):554e8.
[20] Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B,
Jones KD, King Jr TE. Idiopathic nonspecific interstitial pneu-
monia: lung manifestation of undifferentiated connective tis-
sue disease? Am J Respir Crit Care Med 2007;176(7):691e7.
[21] Edwards IR, Aronson JK. Adverse drug reactions: definitions,
diagnosis, and management. Lancet 2000;356:1255e9.
[22] Laszlo G. Standardisation of lung function testing: helpful
guidance from the ATS/ERS Task Force. Thorax 2006;61(9):
744e6.
[23] Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,
Yernault J-C. Lung volumes and forced ventilatory flows.
Report Working Party Standardization of Lung Function Tests,
European Community for Steel and Coal. Official statement of
the European Respiratory Society. Eur Respir J 1993;6(Suppl.
16):5e40.
[24] Silkoff PE, Erzurum SC, Lundberg JO, George SC, Marczin N,
Hunt JF, Effros R, Horvath I., American Thoracic Society; HOC
Subcommittee of the Assembly on Allergy, Immunology, and
Inflammation. ATS workshop proceedings: exhaled nitric oxide
and nitric oxide oxidative metabolism in exhaled breath
condensate. Proc Am Thorac Soc 2006;3(2):131e45.
[25] Malinovschi A, Janson C, Holmkvist T, Norba¨ck D, Merila¨inen P,
Ho¨gman M. Effect of smoking on exhaled nitric oxide and flow-
independent nitric oxide exchange parameters. Eur Respir J
2006;28(2):339e45.
[26] Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Tore´n K.
Height, age, and atopy are associated with fraction of exhaled
nitric oxide in a large adult general population sample. Chest
2006;130(5):1319e25.
1796 L. Guilleminault et al.[27] Nadif R, Matran R, Maccario J, Bechet M, Le Moual N,
Scheinmann P, Bousquet J, Kauffmann F, Pin I. Passive and
active smoking and exhaled nitric oxide levels according to
asthma and atopy in adults. Ann Allergy Asthma Immunol
2010;104(5):385e93.
[28] Lehtima¨ki L, Kankaanranta H, Saarelainen S, Hahtola P,
Ja¨rvenpa¨a¨ R, Koivula T, Turjanmaa V, Moilanen E. Extended
exhaled NO measurement differentiates between alveolar and
bronchial inflammation. Am J Respir Crit Care Med 2001;
163(7):1557e61.
[29] Girgis RE, Gugnani MK, Abrams J, Mayes MD. Partitioning of
alveolar and conducting airway nitric oxide in scleroderma lung
disease. Am J Respir Crit Care Med 2002;165(12):1587e91.
[30] Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L,
Cannizzo S, Bucca C, Morello M, Bergerone S, Bardini D,
Zaccagna A, Puiatti P, Fava C, Cortese G. Exhaled nitric oxide
in systemic sclerosis: relationships with lung involvement and
pulmonary hypertension. J Rheumatol 2000;27(7):1693e8.[31] Wuttge DM, Bozovic G, Hesselstrand R, Aronsson D, Bjermer L,
Scheja A, Tufvesson E. Increased alveolar nitric oxide in early
systemic sclerosis. Clin Exp Rheumatol 2010;(5 Suppl. 62):
S5e9.
[32] Tiev KP, Le-Dong NN, Duong-Quy S, Hua-Huy T, Cabane J,
Dinh-Xuan AT. Exhaled nitric oxide, but not serum nitrite and
nitrate, is a marker of interstitial lung disease in systemic
sclerosis. Nitric Oxide 2009;20(3):200e6.
[33] Moodley YP, Lalloo UG. Exhaled nitric oxide is elevated in
patients with progressive systemic sclerosis without intersti-
tial lung disease. Chest 2001;119(5):1449e54.
[34] Paredi P, Kharitonov SA, Loukides S, Pantelidis P, du Bois RM,
Barnes PJ. Exhaled nitric oxide is increased in active fibrosing
alveolitis. Chest 1999;115(5):1352e6.
[35] Chow S, Campbell C, Sandrini A, Thomas PS, Johnson AR,
Yates DH. Exhaled breath condensate biomarkers in
asbestos-related lung disorders. Respir Med 2009;103(8):
1091e7.
